Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 6

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 6
---
 healthy volunteers and AUD subjects. Upon completion of the Phase I/IIa studies, if successful, we will be required to conduct
additional clinical trials subject to securing additional financing.

About MEAI

MEAI is a synthetic molecule.
Its mechanism of action has been studied and published in the past in scientific papers. It was found to interact with the serotonergic
receptors 5-HT1A and 5-HT2B and the adrenergic receptors α2A, α2B and α2C receptors. The interaction with the 5HT2B
receptor was determined as non-agonist activity. Studies conducted in animals and humans have demonstrated the role of 5-HT1A receptors
in alcohol-drinking behavior. Several 5-HT1A receptor agonists have been tested in animal models to demonstrate the role of this receptor
in alcohol dependence. These preclinical studies suggest that 5-HT1A receptor agonists may play a role in reducing alcohol intake. In
addition, evidence suggests that α2-adrenergic receptor agonist signaling may play a role in mediating alcohol-drinking behavior
in both rodents and humans.

The literature shows that
5-HT1A receptors are associated with controlling craving behaviors across the board. This indicates that MEAI may have a wide range of
applications beyond AUD and binge drinking. Until today, only pre-clinical studies have been conducted with MEAI, including in-vitro and
in-vivo studies. The studies were conducted in the United States, China, France and Israel.

MEAI is a neuroplastogens
non-hallucinogenic molecule, exerting a euphoric alcohol-like experience, and based on human recreational use testimonials and pre-clinical
trials, we believe also reduces the desire to consume alcoholic beverages. While determinations of safety and efficacy are solely within
the authority of the FDA and comparable regulatory bodies, in pre-clinical studies, MEAI was well-tolerated by the tested animals. Although
MEAI remains in development and is not cleared or approved by the FDA or similar foreign regulatory bodies, we believe that our drug candidate
has the potential to change the lives of millions who struggle to drink in moderation.

We believe that MEAI holds
the potential to break the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural
pathways such as 5-HT1A that lead to “sensible behavior”.

Strategic Focus